货号:A354620
同义名:
Brahmic Acid; NSC 88135
Madecassic acid是一种从积雪草(Centella asiatica)草药中分离并纯化的天然产物,具有抗炎作用,通过抑制 iNOS、COX-2、TNF-alpha、IL-1beta 和 IL-6,以及下调 NF-kappaB 激活来实现,表现出对 RAW 264.7 巨噬细胞的抗炎作用。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | eNOS ↓ ↑ | iNOS ↓ ↑ | nNOS ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1400W 2HCl |
+
eNOS, Ki: 50 μM |
++++
iNOS, Kd: <7 nM |
++
nNOS, Ki: 2 μM |
99%+ | |||||||||||||||
| H-Arg(NO2)-OMe·HCl |
+++
eNOS, Ki: 39 nM |
++
iNOS, Ki: 4.4 μM |
+++
nNOS, Ki: 15 nM |
98% | |||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | NF-κB ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ammonium pyrrolidine-1-carbodithioate | ✔ | 98% | |||||||||||||||||
| QNZ |
++++
NF-κB, IC50: 11 nM |
99%+ | |||||||||||||||||
| Sodium 4-Aminosalicylate Dihydrate | ✔ | 98% | |||||||||||||||||
| Sodium Salicylate | ✔ | 95% | |||||||||||||||||
| Parthenolide | ✔ | p53 | 97% HPLC | ||||||||||||||||
| JSH-23 |
+
NF-κB, IC50: 7.1 μM |
98% | |||||||||||||||||
| Phenethyl caffeate | ✔ | 98% | |||||||||||||||||
| Andrographolide | ✔ | 98+% | |||||||||||||||||
| Curcumin | ✔ | Nrf2,HDAC | 98% | ||||||||||||||||
| SC75741 |
+++
NF-κB, EC50: 200 nM |
99%+ | |||||||||||||||||
| CBL0137 HCl |
++
NF-κB, EC50: 0.47 μM |
p53 | 99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | COX ↓ ↑ | COX-1 ↓ ↑ | COX-2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Piroxicam | ✔ | 98% | |||||||||||||||||
| Salicylic acid | ✔ | 98% | |||||||||||||||||
| Phenacetin | ✔ | 98% | |||||||||||||||||
| Etodolac | ✔ | 99% | |||||||||||||||||
| Flunixin meglumine | ✔ | 98% | |||||||||||||||||
| Ibuprofen L-lysine | ✔ | 98% | |||||||||||||||||
| Nabumetone | ✔ | 98% | |||||||||||||||||
| Acemetacin | ✔ | 98% | |||||||||||||||||
| Diflunisal | ✔ | 98% | |||||||||||||||||
| Pranoprofen | ✔ | 98% | |||||||||||||||||
| Ampiroxicam | ✔ | 98% | |||||||||||||||||
| Meloxicam | ✔ | 98% | |||||||||||||||||
| Sulindac | ✔ | 98% | |||||||||||||||||
| Ketoprofen | ✔ | 98% | |||||||||||||||||
| Mefenamic Acid | ✔ | 95% | |||||||||||||||||
| Bromfenac sodium | ✔ | 98% | |||||||||||||||||
| Oxaprozin | ✔ | 99% | |||||||||||||||||
| Aspirin | ✔ | 99% | |||||||||||||||||
| Nepafenac | ✔ | 98% | |||||||||||||||||
| Zaltoprofen | ✔ | 99% | |||||||||||||||||
| Salicin | ✔ | 98% | |||||||||||||||||
| Suprofen | ✔ | 99%+ | |||||||||||||||||
| Xanthohumol | ✔ | 99% | |||||||||||||||||
| Parecoxib | ✔ | 98% | |||||||||||||||||
| Tolfenamic Acid |
+++
COX-2, IC50: 0.2 μM |
98% | |||||||||||||||||
| Etoricoxib | ✔ | 99% | |||||||||||||||||
| Niflumic Acid | ✔ | 98% | |||||||||||||||||
| Valdecoxib |
++++
COX-2, IC50: 5 nM |
99+% | |||||||||||||||||
| Ibuprofen |
+
COX-1, IC50: 13 μM |
+
COX-2, IC50: 370 μM |
98% | ||||||||||||||||
| Indomethacin |
++
COX1, IC50: 0.28 μM |
+
COX-2, IC50: 14 μM |
97% | ||||||||||||||||
| Lornoxicam |
++++
COX-1, IC50: 5 nM |
++++
COX-2, IC50: 8 nM |
98% | ||||||||||||||||
| Meclofenamic acid sodium |
++++
COX-1, IC50: 40 nM |
+++
COX-2, IC50: 50 nM |
99% | ||||||||||||||||
| Asaraldehyde | ✔ | 98% | |||||||||||||||||
| Naproxen |
+
COX-1, IC50: 8.7 μM |
+
COX-2, IC50: 5.2 μM |
98% | ||||||||||||||||
| Diclofenac Sodium Salt |
+++
COX-1, IC50: 60 nM |
+++
COX-2, IC50: 200 nM |
98% | ||||||||||||||||
| NS-398 |
++
COX-2, IC50: 3.8 μM |
95% | |||||||||||||||||
| Amfenac Sodium Hydrate |
++
COX-1, IC50: 250 nM |
+++
COX-2, IC50: 150 nM |
98%+ | ||||||||||||||||
| Nimesulide |
+
COX-2, IC50: 26 μM |
98% | |||||||||||||||||
| Lumiracoxib |
++
COX-1, Ki: 3 μM |
+++
COX-2, Ki: 60 nM |
98% | ||||||||||||||||
| Rutaecarpine | ✔ | 95% | |||||||||||||||||
| Celecoxib |
++++
COX-2, IC50: 40 nM |
98% | |||||||||||||||||
| Carprofen |
++++
canine COX2, IC50: 30 nM |
98% | |||||||||||||||||
| Ketorolac |
++
COX-1 (human), IC50: 1.23 μM |
++
COX-2 (human), IC50: 3.50 μM |
98% | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Madecassic acid, a natural product isolated and purified from the herbs of Centella asiatica (L.) Urban, has anti-inflammatory properties by iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6 inhibition via the downregulation of NF-kappaB activation in RAW 264.7 macrophage cells. |
| Concentration | Treated Time | Description | References | |
| Escherichia coli | 250 µg/mL | Inhibit the growth of Escherichia coli | Molecules. 2023 Feb 16;28(4):1895 | |
| A431 cells | 20 μM | 24 hours | MA inhibited tumor cell proliferation, migration and invasion, and enhanced the anticancer effect of DOX. | Int J Biol Sci. 2024 Oct 7;20(14):5396-5414 |
| HepG2 cells | 20 μM | 24 hours | MA inhibited tumor cell proliferation, migration and invasion, and enhanced the anticancer effect of DOX. | Int J Biol Sci. 2024 Oct 7;20(14):5396-5414 |
| MCF-7 cells | 20 μM | 24 hours | MA inhibited tumor cell proliferation, migration and invasion, and enhanced the anticancer effect of DOX. | Int J Biol Sci. 2024 Oct 7;20(14):5396-5414 |
| NMVMs | 5 μM | 24 hours | MA pretreatment attenuated the DOX-induced decrease in the mitochondrial membrane potential, reduced mitochondrial fission, and maintained the number and morphology of the mitochondria. | Int J Biol Sci. 2024 Oct 7;20(14):5396-5414 |
| H9c2 cells | 5 μM | 24 hours | MA pretreatment significantly attenuated DOX-induced cardiomyocyte injury and cell death, inhibited ROS accumulation and MDA production. | Int J Biol Sci. 2024 Oct 7;20(14):5396-5414 |
| γδT17 cells | 1, 3, 10 μM | 72 hours | Inhibited the activation of γδT17 cells and reduced IL-17A expression | Cell Death Dis. 2020 Sep 14;11(9):752 |
| RAW264.7 macrophages | 10 µM | 18 hours | To evaluate the protective effect of madecassic acid against LPS-induced oxidative stress. Results showed that madecassic acid significantly reduced NO, TNF-α, and IL-6 production. | Antioxidants (Basel). 2024 Apr 18;13(4):483 |
| EA.hy926 endothelial cells | 2.5 µM | 2 hours | To evaluate the protective effect of madecassic acid against H2O2-induced endothelial cell damage. Results showed that madecassic acid significantly increased cell viability, reduced ROS production, and restored GSH levels. | Antioxidants (Basel). 2024 Apr 18;13(4):483 |
| HepG2 hepatocytes | 5 µM | 24 hours | To evaluate the protective effect of madecassic acid against TBHP-induced hepatocyte damage. Results showed that madecassic acid significantly increased cell viability, reduced ROS production, and decreased ALT and AST levels. | Antioxidants (Basel). 2024 Apr 18;13(4):483 |
| Hs68 human skin fibroblasts | 10 µM | 24 hours | To evaluate the protective effect of madecassic acid against UVB-induced oxidative stress. Results showed that madecassic acid significantly increased cell viability, reduced ROS and MDA production, and restored GSH levels. | Antioxidants (Basel). 2024 Apr 18;13(4):483 |
| Bacillus megaterium | 62.5 µg/mL | Inhibit the growth of Bacillus megaterium | Molecules. 2023 Feb 16;28(4):1895 | |
| Bacillus subtilis | 62.5 µg/mL | Inhibit the growth of Bacillus subtilis | Molecules. 2023 Feb 16;28(4):1895 | |
| Pseudomonas aeruginosa | 125 µg/mL | Inhibit the growth of Pseudomonas aeruginosa | Molecules. 2023 Feb 16;28(4):1895 | |
| NIH 3T3 (non-malignant fibroblasts) | >30 µM | 72 hours | Evaluation of cytotoxicity, results showed low cytotoxicity | Int J Mol Sci. 2022 Apr 14;23(8):4362 |
| A2780 (ovarian carcinoma) | >30 µM | 72 hours | Evaluation of cytotoxicity, results showed low cytotoxicity | Int J Mol Sci. 2022 Apr 14;23(8):4362 |
| MCF7 (breast adenocarcinoma) | >30 µM | 72 hours | Evaluation of cytotoxicity, results showed low cytotoxicity | Int J Mol Sci. 2022 Apr 14;23(8):4362 |
| HT29 (colorectal carcinoma) | >30 µM | 72 hours | Evaluation of cytotoxicity, results showed low cytotoxicity | Int J Mol Sci. 2022 Apr 14;23(8):4362 |
| A375 (melanoma) | >30 µM | 72 hours | Evaluation of cytotoxicity, results showed low cytotoxicity | Int J Mol Sci. 2022 Apr 14;23(8):4362 |
| IL-1β-induced rat primary chondrocytes | 10 µM | 48 hours | MA protected chondrocytes against ECM degradation by upregulating collagen-II and ACAN expression and downregulating MMP-3 and MMP-13 expression. | Drug Des Devel Ther. 2022 Nov 1;16:3793-3804 |
| Rat primary chondrocytes | 10 µM | 48 hours | Assessed the effect of MA on chondrocyte viability, finding that 10 µM MA significantly increased chondrocyte viability. | Drug Des Devel Ther. 2022 Nov 1;16:3793-3804 |
| Methicillin-resistant Staphylococcus aureus | 62.5 µg/mL | Inhibit the growth of Methicillin-resistant Staphylococcus aureus | Molecules. 2023 Feb 16;28(4):1895 | |
| Staphylococcus aureus | 31.25 µg/mL | 28 hours | Inhibit the growth of Staphylococcus aureus | Molecules. 2023 Feb 16;28(4):1895 |
| human liver microsomes | 0.12 µM | Evaluation of reversible inhibition of CYP2C9 by CAW-R61J, IC50 of 330 mg/ml | Drug Metab Dispos. 2020 Oct;48(10):1053-1063 | |
| EL-4 mouse lymphoma cells | 1, 3, 10 μM | 24 hours | Madecassic acid promoted the expression of PPARγ-responsive genes CD36 and LPL, indicating its role as a PPARγ agonist. | Cell Death Dis. 2017 Mar 30;8(3):e2723 |
| Mouse CD4+ T cells | 3, 10 μM | 4 days | Madecassic acid reduced the percentage of CD4+IL-17+ T cells and increased the percentage of CD4+Foxp3+ T cells under Th17-polarizing conditions, indicating it promoted the shift of Th17 toward Treg cells. | Cell Death Dis. 2017 Mar 30;8(3):e2723 |
| Administration | Dosage | Frequency | Description | References | ||
| C57BL/6J male mice | DOX-induced acute heart failure mouse model | Gavage | 25 mg/kg/day | Daily for 12 days | MA pretreatment significantly attenuated DOX-induced myocardial injury, improved cardiac function, and inhibited myocardial fibrosis and inflammatory response. | Int J Biol Sci. 2024 Oct 7;20(14):5396-5414 |
| Female C57BL/6 mice | DSS-induced colitis model | Oral | 25 mg/kg/day | Once daily for 10 days | Reduced the number of γδT17 cells and attenuated colon inflammation | Cell Death Dis. 2020 Sep 14;11(9):752 |
| Sprague-Dawley rats | Oral | 100 mg/kg | Single dose | Improved bioavailability | Int J Nanomedicine. 2023 May 8;18:2345-2358 | |
| Balb/cA mice | Diabetic mice model | Dietary intake | 0.05% or 0.1% | Six weeks | Improved glycemic control, lowered lipid accumulation, attenuated oxidative and inflammatory stress | Nutrients. 2015 Dec 2;7(12):10065-75 |
| Sprague-Dawley rats | OA model induced by anterior cruciate ligament transection (ACLT) | Intra-articular injection | 1 mg/kg | Daily for one week, then once every three days for three weeks | MA inhibited cartilage matrix degradation and delayed cartilage surface degeneration, slowing OA progression. | Drug Des Devel Ther. 2022 Nov 1;16:3793-3804 |
| C57BL/6 mice | DSS-induced colitis model | Oral | 12.5, 25 mg/kg | Consecutive 10 days | Madecassic acid alleviated DSS-induced colitis in mice by restoring the Th17/Treg balance, decreasing the percentage of Th17 cells and increasing the percentage of Treg cells. | Cell Death Dis. 2017 Mar 30;8(3):e2723 |
| ICR mice | Bleomycin-induced pulmonary fibrosis model | Oral | 10, 20 mg/kg | Once daily for 21 days | To evaluate the effect of madecassic acid on bleomycin-induced pulmonary fibrosis. Results showed that madecassic acid had no significant effect on pulmonary fibrosis. | Br J Pharmacol. 2016 Apr;173(7):1219-35 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.98mL 0.40mL 0.20mL |
9.91mL 1.98mL 0.99mL |
19.81mL 3.96mL 1.98mL |
|
| CAS号 | 18449-41-7 |
| 分子式 | C30H48O6 |
| 分子量 | 504.7 |
| SMILES Code | C[C@@]1(CO)[C@@H](O)[C@H](O)C[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3C[C@@H](O)[C@@]12[H] |
| MDL No. | MFCD11559128 |
| 别名 | Brahmic Acid; NSC 88135 |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 60 mg/mL(118.88 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1